ZyVersa Therapeutics entered into a warrant exercise inducement agreement on November 5, 2024, allowing holders to exercise existing warrants at a reduced price of $2.06 per share, potentially generating gross proceeds of $1.7 million. The existing warrants include Series A, B, A-1, and B-1 warrants originally issued in December 2023 and August 2024.As part of the agreement, the company will issue new Series A-2 Inducement Warrants to participating holders, representing 200% of the shares issued from existing warrant exercises. These new warrants will be exercisable at $2.06 per share with a 5-year term. The company engaged A.G.P./Alliance Global Partners as financial advisor for a $110,000 fee plus expenses.The issuance of shares underlying the Inducement Warrants requires stockholder approval under Nasdaq rules. ZyVersa commits to filing an S-3 registration statement by December 20, 2024, for the resale of shares underlying the Inducement Warrants. The proceeds will be used for working capital and general corporate purposes.

ZyVersa Therapeutics entered into a warrant exercise inducement agreement on November 5, 2024, allowing holders to exercise existing warrants at a reduced price of $2.06 per share, potentially generating gross proceeds of $1.7 million. The existing warrants include Series A, B, A-1, and B-1 warrants originally issued in December 2023 and August 2024.As part of the agreement, the company will issue new Series A-2 Inducement Warrants to participating holders, representing 200% of the shares issued from existing warrant exercises. These new warrants will be exercisable at $2.06 per share with a 5-year term. The company engaged A.G.P./Alliance Global Partners as financial advisor for a $110,000 fee plus expenses.The issuance of shares underlying the Inducement Warrants requires stockholder approval under Nasdaq rules. ZyVersa commits to filing an S-3 registration statement by December 20, 2024, for the resale of shares underlying the Inducement Warrants. The proceeds will be used for working capital and general corporate purposes.